Yearly STL Archives: 2025

The OX40-OX40 ligand pathway has emerged as a promising therapeutic target for moderate-to-severe atopic dermatitis, offering a novel approach that simultaneously addresses multiple inflammatory pathways involved in disease pathogenesis. This review examines phase II clinical trial data for three monoclonal antibodies targeting this pathway: amlitelimab, rocatinlimab, and telazorlimab.

Neoadjuvant cemiplimab has shown promising results for resectable cutaneous squamous cell carcinoma where surgery may result in significant morbidity. Phase 2 studies demonstrated pathological complete response rates of 51% with event-free survival of 89% at 12 months. The treatment was well-tolerated and may improve surgical outcomes by reducing tumor burden before resection, offering a valuable option for advanced disease.

Update on Guselkumab SC use (Tremfya®), Remibrutinib tablets (Rhapsido®), Pembrolizumab + berahyaluronidase alfapmph SC injection (Keytruda Qlex®), Donidalorsen SC use (Dawnzera), Garadacimab for SC use (Andembry®), and Lifileucel for IV use (Amtagvi®)

Health Canada approved selumetinib in 2022 for treating inoperable plexiform neurofibromas in children with neurofibromatosis type 1. Clinical trials showed 74% of patients experienced significant tumor shrinkage, with improvements in pain and quality of life. The oral MEK inhibitor offers the first targeted therapy for these historically difficult-to-treat nerve tumors.

Upadacitinib shows sustained long-term efficacy and safety for moderate-to-severe atopic dermatitis in 76-week studies. The oral JAK inhibitor maintains 80%+ EASI-75 response rates with manageable side effects, outperforming dupilumab in head-to-head trials while offering faster symptom relief for chronic eczema patients.

Update on Delgocitinib cream (Anzupgo®), Recombinant zoster vaccine (Shingrix®), Sebetralstat tablets (Ekterly®), and Lifileucel for IV infusion (Amtagvi®).

Skin aging, caused by a combination of intrinsic and extrinsic factors, leads to decreased collagen, elastin and hydration levels with subsequent volume loss, dullness, uneven skin tone and fine lines, among other undesirable features. Individuals, especially youth, have become increasingly interested in slowing or preventing the aging process, given the impact of skin appearance on one’s self-esteem, social interactions and overall quality of life...

Real-world evidence from 7 Canadian cases shows tildrakizumab effectively treats moderate-to-severe psoriasis with excellent safety profile and patient satisfaction.

Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab.

Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects.

Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™).

Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favorable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods.

IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes.

Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®).

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.

Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™).

Explore a comprehensive overview of pediatric hidradenitis suppurativa (HS), a chronic inflammatory skin condition. This article delves into its epidemiology, pathogenesis, clinical features, associated comorbidities, and treatment challenges. Gain insights into the unique aspects of pediatric HS, including its impact on quality of life and the importance of early diagnosis and management.

Discover the latest insights into managing cutaneous leishmaniasis (CL), including its epidemiology, prevention, diagnosis, and treatment advancements. This article highlights rising global cases, travel-related risks, and evolving clinical strategies to combat this neglected tropical disease.

Update on Cosibelimab-ipdl IV use (Unloxcyt™), Ustekinumab-kfce SC/IV use (Yesintek™), Minocycline hydrochloride capsules (Emrosi™).